Pathways targeted by antidiabetes drugs are enriched for multiple genes associated with type 2 diabetes risk

Diabetes

Volumn 64, Issue 4, 2015, Pages 1470-1483

  Segrè, Ayellet V ^a,b   Wei, Nancy ^b,c   Altshuler, David ^a,b,c   Florez, Jose C ^a,b,c  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; ACYL COA SYNTHETASE LONG CHAIN FAMILY MEMBER 1 PROTEIN; ALPHA GLUCOSIDASE INHIBITOR; AMYLIN DERIVATIVE; ANTIDIABETIC AGENT; ATP BINDING CASSETTE SUBFAMILY C MEMBER 8 PROTEIN; CXCL11 CHEMOKINE; CXCL9 CHEMOKINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GASTRIC INHIBITORY POLYPEPTIDE; GASTRIN RELEASING PEPTIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCAGON LIKE PEPTIDE 2 RECEPTOR; GLUCOSE TRANSPORTER 2; INCRETIN; INSULIN; INSULIN RECEPTOR SUBSTRATE 2; INSULINASE; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEGLITINIDE; METFORMIN; NUCLEAR FACTOR OF KAPPA LIGHT POLYPEPTIDE GENE ENHANCER IN BETA CELLS 1 PROTEIN; PEPTIDES AND PROTEINS; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; SULFONYLUREA DERIVATIVE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; DIABETOGENESIS; DRUG TARGETING; FOLLOW UP; GENE REPLICATION; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; INSULIN TREATMENT; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE;

DATABASES, GENETIC; DIABETES MELLITUS, TYPE 2; GENE REGULATORY NETWORKS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPOGLYCEMIC AGENTS; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84962028185     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db14-0703     Document Type: Article

References (48)

1. McCarthy MI. Genomics, type 2 diabetes, and obesity. N Engl J Med 2010; 363: 2339-2350
2. Billings LK, Florez JC. The genetics of type 2 diabetes: What have we learned from GWAS? Ann N Y Acad Sci 2010;1212: 59-77
3. Morris AP, Voight BF, Teslovich TM, et al.; Wellcome Trust Case Control Consortium; Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC) Investigators; Genetic Investigation of ANthropometric Traits (GIANT) Consortium; Asian Genetic Epidemiology Network-Type 2 Diabetes (AGEN-T2D) Consortium; South Asian Type 2 Diabetes (SAT2D) Consortium; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analysis provides insights into the genetic architecture and pathophysiology of type 2 diabetes. Nat Genet 2012;44: 981-990
4. Stahl EA, Wegmann D, Trynka G, et al.; Diabetes Genetics Replication and Meta-analysis Consortium; Myocardial Infarction Genetics Consortium. Bayesian inference analyses of the polygenic architecture of rheumatoid arthritis. Nat Genet 2012;44: 483-489
5. Lee SH, Wray NR, Goddard ME, Visscher PM. Estimating missing heritability for disease from genome-wide association studies. Am J Hum Genet 2011;88: 294-305
6. Prokopenko I, Langenberg C, Florez JC, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet 2009;41: 77-81
7. Dupuis J, Langenberg C, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; Global BPgen Consortium; Anders Hamsten on behalf of Procardis Consortium; MAGIC Investigators. New genetic loci implicated in fasting glucose homeostasis and their impact on type 2 diabetes risk. Nat Genet 2010;42: 105-116
8. Saxena R, Hivert MF, Langenberg C, et al.; GIANT Consortium; MAGIC Investigators. Genetic variation in GIPR influences the glucose and insulin responses to an oral glucose challenge. Nat Genet 2010;42: 142-148
9. Soranzo N, Sanna S, Wheeler E, et al. Common variants at 10 genomic loci influence hemoglobin A1(C) levels via glycemic and nonglycemic pathways [published correction appears in Diabetes 2011;60: 1050-1051]. Diabetes 2010; 59: 3229-3239
10. Strawbridge RJ, Dupuis J, Prokopenko I, et al.; DIAGRAM Consortium; GIANT Consortium; MuTHER Consortium; CARDIoGRAM Consortium; C4D Consortium. Genome-wide association identifies nine common variants associated with fasting proinsulin levels and provides new insights into the pathophysiology of type 2 diabetes. Diabetes 2011;60: 2624-2634
11. Manning AK, Hivert M-F, Scott RA, et al. A genome-wide approach accounting for body mass index identifies genetic variants influencing fasting glycemic traits and insulin resistance. Nat Genet 2012;44: 659-669
12. Voight BF, Kang HM, Ding J, et al. The metabochip, a custom genotyping array for genetic studies of metabolic, cardiovascular, and anthropometric traits. PLoS Genet 2012;8: E1002793
13. Scott RA, Lagou V, Welch RP, et al.; DIAbetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium. Large-scale association analyses identify new loci influencing glycemic traits and provide insight into the underlying biological pathways. Nat Genet 2012;44: 991-1005
14. Altshuler D, Hirschhorn JN, Klannemark M, et al. The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet 2000;26: 76-80
15. Gloyn AL, Weedon MN, Owen KR, et al. Large-scale association studies of variants in genes encoding the pancreatic β-cell KATP channel subunits Kir6.2 (KCNJ11) and SUR1 (ABCC8) confirm that the KCNJ11 E23K variant is associated with type 2 diabetes. Diabetes 2003;52: 568-572
16. Doyle ME, Egan JM. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007;113: 546-593
17. Buteau J. GLP-1 receptor signaling: Effects on pancreatic beta-cell proliferation and survival. Diabetes Metab 2008;34(Suppl. 2): S73-S77
18. Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J Am Pharm Assoc (2003) 2009;49(Suppl. 1): S16-S29
19. Saltiel AR, Kahn CR. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 2001;414: 799-806
20. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996;334: 574-579
21. Rosen ED, Spiegelman BM. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276: 37731-37734
22. Yki-Järvinen H. Thiazolidinediones. N Engl J Med 2004;351: 1106-1118
23. Müller G. The molecular mechanism of the insulin-mimetic/sensitizing activity of the antidiabetic sulfonylurea drug Amaryl. Mol Med 2000;6: 907-933
24. Renström E, Barg S, Thévenod F, Rorsman P. Sulfonylurea-mediated stimulation of insulin exocytosis via an ATP-sensitive K+ channel-independent action. Diabetes 2002;51(Suppl. 1): S33-S36
25. Proks P, Reimann F, Green N, Gribble F, Ashcroft F. Sulfonylurea stimulation of insulin secretion. Diabetes 2002;51(Suppl. 3): S368-S376
26. Drucker DJ. Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: Preclinical biology and mechanisms of action. Diabetes Care 2007;30: 1335-1343
27. Ryan GJ, Jobe LJ, Martin R. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus. Clin Ther 2005;27: 1500-1512
28. Malaisse WJ. Mechanism of action of a new class of insulin secretagogues. Exp Clin Endocrinol Diabetes 1999;107(Suppl. 4): S140-S143
29. Martin AE, Montgomery PA. Acarbose: An alpha-glucosidase inhibitor. Am J Health Syst Pharm 1996;53: 2277-2290; quiz 2336-2337
30. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Ann Intern Med 2002;137: 25-33
31. Chang AY, Wyse BM, Gilchrist BJ. Ciglitazone, a new hypoglycemic agent. II. Effect on glucose and lipid metabolisms and insulin binding in the adipose tissue of C57BL/6J-ob/ob and 2 + / ? mice. Diabetes 1983;32: 839-845
32. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995;270: 12953-12956
33. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature 2010;466: 707-713
34. Segrè AV, Groop L, Mootha VK, Daly MJ, Altshuler D; DIAGRAM Consortium; MAGIC Investigators. Common inherited variation in mitochondrial genes is not enriched for associations with type 2 diabetes or related glycemic traits. PLoS Genet 2010;6: E1001058
35. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356: 2457-2471
36. Mahaffey KW, Hafley G, Dickerson S, et al. Results of a reevaluation of cardiovascular outcomes in the RECORD trial. Am Heart J 2013;166: 240-249
37. Tannen R, Xie D, Wang X, Yu M, Weiner MG. A new "comparative effectiveness" assessment strategy using the THIN database: Comparison of the cardiac complications of pioglitazone and rosiglitazone. Pharmacoepidemiol Drug Saf 2013;22: 86-97
38. Zeggini E, Scott LJ, Saxena R, et al.; Wellcome Trust Case Control Consortium. Meta-analysis of genome-wide association data and large-scale replication identifies additional susceptibility loci for type 2 diabetes. Nat Genet 2008; 40: 638-645
39. Voight BF, Scott LJ, Steinthorsdottir V, et al.; MAGIC Investigators; GIANT Consortium. Twelve type 2 diabetes susceptibility loci identified through largescale association analysis. Nat Genet 2010;42: 579-589
40. Yasuda K, Miyake K, Horikawa Y, et al. Variants in KCNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat Genet 2008;40: 1092-1097
41. Unoki H, Takahashi A, Kawaguchi T, et al. SNPs in KCNQ1 are associated with susceptibility to type 2 diabetes in East Asian and European populations. Nat Genet 2008;40: 1098-1102
42. Rung J, Cauchi S, Albrechtsen A, et al. Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia. Nat Genet 2009;41: 1110-1115
43. Kooner JS, Saleheen D, Sim X, et al.; DIAGRAM; MuTHER. Genome-wide association study in individuals of South Asian ancestry identifies six new type 2 diabetes susceptibility loci. Nat Genet 2011;43: 984-989
44. Saxena R, Elbers CC, Guo Y, et al.; Look AHEAD Research Group; DIAGRAM Consortium. Large-scale gene-centric meta-analysis across 39 studies identifies type 2 diabetes loci [published correction appears in Am J Hum Genet 2012;90: 753]. Am J Hum Genet 2012;90: 410-425
45. Peer I, Yelensky R, Altshuler D, Daly MJ. Estimation of the multiple testing burden for genomewide association studies of nearly all common variants. Genet Epidemiol 2008;32: 381-385
46. Plenge RM, Scolnick EM, Altshuler D. Validating therapeutic targets through human genetics. Nat Rev Drug Discov 2013;12: 581-594
47. Jablonski KA, McAteer JB, de Bakker PI, et al.; Diabetes Prevention Program Research Group. Common variants in 40 genes assessed for diabetes incidence and response to metformin and lifestyle interventions in the Diabetes Prevention Program. Diabetes 2010;59: 2672-2681
48. Okada Y, Wu D, Trynka G, et al.; RACI Consortium; GARNET Consortium. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 2014;506: 376-381